We have previously shown that HER2 expression can promote FOXO3 cytoplasmic localisation via activating AKT [11, 50, 51], and this could account for the observation that 95.7% of the 447 HER2+ breast cancer cases have cytoplasmic FOXO3 expression [52]. The gene discussed is ERBB2; the disease is breast cancer.